2012 Press Releases

Keyword Search
 
DateTitle  
22-Nov-2012ERYTECH Pharma signs licensing and distribution agreement with Orphan Europe for GRASPA® in Europe
LYON, France--(BUSINESS WIRE)--ERYTECH Pharma, a late stage biopharmaceuticals company focused on orphan oncology and rare diseases, announced today that it has entered into a definitive agreement with Orphan Europe, part of the Recordati Group, granting Orphan Europe exclusive rights for the commercialization and distribution of GRASPA® in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) in Europe. GRASPA®, L-asparaginase encapsulated into human erythrocytes, for the treat... 
Download PDFPrinter Friendly Version
07-Sep-2012ERYTECH Pharma announces the oral presentation of very demonstrative results regarding its technology to Induce specific immune tolerance by antigen loaded erythrocytes.
ERYTECH Pharma announces the oral presentation of very demonstrative results regarding its technology to Induce specific immune tolerance by antigen loaded erythrocytes.   Therapeutic proteins are often immunogenic, inducing anaphylactic reactions and/or specific immunoglobulins. Their administration is often stopped or inefficient due to neutralizing antibodies. ERYTECH’s concept consists in encapsulating the therapeutic proteins inside erythrocytes. The membrane of the erythrocytes is mo... 
Download PDFPrinter Friendly Version
17-Jul-2012ERYTECH Pharma announces the oral presentation of positive Phase II clinical trial results in Acute Lymphoblastic Leukemia
ERYTECH Pharma Announces the Oral Presentation of Positive Phase II Clinical Trial Results in Acute Lymphoblastic Leukemia June 17, 2012 05:00 AM Eastern Daylight Time LYON, France--(BUSINESS WIRE)--The oral presentation will be held on June 17th 2012 by Prof. Dr. Hervé Dombret, Hospital Saint Louis, Paris (France) at the 17th Annual Meeting of European Hematology Association (EHA) in Amsterdam (The Netherlands). Thirty patients over 55-years old, newly diagnosed with Acut... 
Download PDFPrinter Friendly Version
13-Jun-2012ERYTECH Pharma’s sickle cell treatment receives positive opinion for Orphan Drug Designation from the European Medicines Agency
ERYTECH Pharma’s Sickle Cell Treatment Receives Positive Opinion for Orphan Drug Designation from the European Medicines Agency June 13, 2012 08:00 AM Eastern Daylight Time LYON, France--(BUSINESS WIRE)--ERYTECH Pharma, a late stage biopharmaceuticals company focused on orphan oncology and rare diseases, announces that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) adopted a positive opinion to grant Orphan Drug Designation (ODD) t... 
Download PDFPrinter Friendly Version
05-Jun-2012ERYTECH Pharma receives € 7 million from OSEO to lead the TEDAC personalized medicine project in cancer
ERYTECH Pharma Receives € 7 Million from OSEO to Lead the TEDAC Personalized Medicine Project in Cancer Financing of € 6.95 million through grants and redeemable advances from the French public organization OSEO Leader of the collaborative project that aims to create major innovations within a unique worldwide consortium Further optimizing a new paradigm for the treatment of fragile cancer patients through well targeted tumor starvation ... 
Download PDFPrinter Friendly Version
Top